Skip to main content

Table 2 Elevated metabolic abnormalities and depression in breast cancer survivors

From: Increased depression and metabolic risk in postmenopausal breast cancer survivors

  Control N = 28 BCS N = 28
Systolic blood pressure (mmHg) 121 ± 3 122 ± 2
Diastolic blood pressure (mmHg) 68 ± 1 68 ± 1
Hypertension medication usage (%) 43 56
Fasting glucose (mmol/L) 5.2 ± 0.1 5.7 ± 0.2b
Fasting insulin (pmol/L) 86 ± 7 97 ± 15
HOMA-IR 3.3 ± 0.3 4.1 ± 0.6
2-hr glucose (mmol/L) 7.1 ± 0.4 6.6 ± 0.6
Cholesterol (mmol/L) 4.8 ± 0.1 5.2 ± 0.2a
Triglycerides (mmol/L) 1.2 ± 0.1 1.4 ± 0.1
HDL-C (mmol/L) 1.4 ± 0.1 1.7 ± 0.1b
LDL-C (mmol/L) 2.8 ± 0.1 2.9 ± 0.2
Lipid lowering medication usage (%) 11 50c
Metabolic syndrome components (#) 1.7 ± 0.2 2.4 ± 0.3b
CES-D 6 ± 1 6 ± 1
Antidepressant medication usage (%) 14 43b
  1. Mean ± SEM
  2. HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; CES-D Center for Epidemiologic Studies Depression Scale
  3. Different than control: P = 0.08; b P < 0.05; c P < 0.01